Although the agency stated that Veru Inc’s experimental drug for COVID-19 met the main goal of reducing the death rate in a late-stage trial, it flagged a number of uncertainties with the data.
https://www.pharmalive.com/wp-content/uploads/2022/04/ReutersFDAsign.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-11-07 10:11:002022-11-07 10:22:21FDA staff flags several uncertainties with Veru’s COVID-19 drug
